SCHEMBL30298024

SCHEMBL30298024

O=C(O)c1cn(-c2ccc(O)c(F)c2)c2cc(N3Cc4cccnc4C3)c(Cl)cc2c1=O

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
CAPN1 P07384 3/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
PIK3CG P48736 4/20 0.41
RORC P51449 3/20 0.40
POLB P06746 1/20 0.39
HSP90AA1 P07900 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
TIPARP Q7Z3E1 1/20 0.37
GRM1 Q13255 1/20 0.37
PIK3CD O00329 2/20 0.37
PIK3R1 P27986 2/20 0.37
PIK3CA P42336 2/20 0.37
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31157443 0.93 LMNA (0.54) LMNAMEN1KMT2ACAPN1KDM4E
SCHEMBL31157413 0.89 CAPN1 (0.48) LMNAMEN1KMT2ACAPN1KDM4E
SCHEMBL30298023 0.89 NPC1 (0.43) LMNAMEN1KMT2ACAPN1KDM4E
SCHEMBL31157434 0.88 LMNA (0.44) LMNAMEN1KMT2ACAPN1KDM4E
SCHEMBL31157548 0.87 LMNA (0.42) LMNAMEN1KMT2ACAPN1KDM4E
SCHEMBL31157491 0.86 CAPN1 (0.43) LMNAMEN1KMT2ACAPN1KDM4E
SCHEMBL30298075 0.85 LMNA (0.41) LMNAMEN1KMT2ACAPN1KDM4E
Hydrochloric Acid SCHEMBL31157585 0.85 TIPARP (0.41) LMNAMEN1KMT2ACAPN1KDM4E
SCHEMBL30298047 0.85 TIPARP (0.40) CAPN1HSP90AA1TIPARPGRM1
SCHEMBL31157556 0.84 LMNA (0.58) LMNAMEN1KMT2ACAPN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376100-A1 PAPD5 AND/OR PAPD7 INHIBITING 4-OXO-1, 4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES Redona Therapeutics, Inc. 2024-11-14 US disclosed
EP-4399206-A1 PAPD5 AND/OR PAPD7 INHIBITING 4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES Redona Therapeutics, Inc. (US) 2024-07-17 EP disclosed
CN-118201914-A 4-Oxo-1, 4-dihydroquinoline-3-carboxylic acid derivatives as PAPD5 and/or PAPD7 inhibitors 雷多纳治疗公司 2024-06-14 CN disclosed
WO-2023039089-A1 PAPD5 AND/OR PAPD7 INHIBITING 4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES TWENTYEIGHT-SEVEN, INC. (US) 2023-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376100-A1 PAPD5 AND/OR PAPD7 INHIBITING 4-OXO-1, 4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES PAPSS1, OTUD7B, BRD7 LMNA 3801/4885MEN1 3213/4885KMT2A 2390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.